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Summary objective To compare the safety/tolerability of abacavir and nevirapine in HIV-infected adults starting
antiretroviral (ARV) therapy in Uganda.
methods Twenty-four-week randomized double-blind trial conducted with 600 symptomatic ARV-
naive adults with CD4 <200 cells/mm
3 allocated to zidovudine/lamivudine plus 300 mg abacavir (A)
and nevirapine placebo (n = 300) or 200 mg nevirapine (N) and abacavir placebo (n = 300) twice daily.
The primary endpoint was any serious adverse event (SAE) deﬁnitely/probably or uncertain whether
related to blinded nevirapine/abacavir. Secondary endpoints were adverse events leading to permanent
discontinuation of blinded nevirapine/abacavir, and grade 4 events.
results Seventy-two per cent participants were women; 19% had WHO stage 4 disease; the median
age was 37 years (range 18–66); the median baseline CD4 count was 99 cells/mm
3 (1–199). Ninety-ﬁve
per cent completed 24 weeks: 4% died and 1% were lost to follow-up. Thirty-seven SAEs occurred
on blinded drug in 36 participants. Twenty events [6 (2.0%) abacavir, 14 (4.7%) nevirapine partici-
pants] were considered serious adverse reactions deﬁnitely/probably/uncertain whether related to blin-
ded abacavir/nevirapine [HR = 0.42 (95% CI 0.16–1.09) P = 0.06]. Only 2.0% of abacavir participants
[six patients (0.7–4.3%)] experienced a suspected hypersensitivity reaction (HSR). In total 14 (4.7%)
abacavir and 30 (10.0%) nevirapine participants discontinued blinded abacavir/nevirapine (P = 0.02):
because of toxicity (6A, 15N; P = 0.07, all rash/possible HSR and/or hepatotoxicity), anti-tuberculosis
therapy (6A, 13N), or for other reasons (2A, 2N).
conclusions There was a trend towards a lower rate of serious adverse reactions in Ugandan adults
with low CD4 starting ARV regimens with abacavir than with nevirapine. This suggests that abacavir
could be used more widely in resource-limited settings without major safety concerns.
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Introduction
The ﬁrst-line regimen recommended by WHO in resource-
limited settings is two nucleoside/nucleotide reverse trans-
criptase inhibitors (NRTIs) plus a non-nucleoside reverse
transcriptase inhibitor (NNRTI) (WHO 2006). Nevirapine
has been the most frequently used NNRTI, primarily
because of low cost and incorporation into ﬁxed dose
combinations: the alternative NNRTI, efavirenz, is con-
traindicated in pregnancy and is therefore problematic in
settings with a high proportion of women of child-
bearing potential. Rash and hepatoxicity are the most
common toxicities associated with nevirapine. Rashes
occur in 15–20% of subjects (de Maat et al. 2003;
Montaner et al. 2003). They are severe, life-threatening
or fatal in 2–5% subjects (van Leeuwen et al. 2003), and
cause discontinuation in around 7% (Knobel et al. 2004;
van Leth et al. 2004). First-line therapy with 2NRTI/
NNRTI is limited by interactions between NNRTIs and
anti-tuberculosis treatment; hepatotoxicity of nevirapine
in those with higher CD4 counts [particularly women
(van Leth et al. 2005) 1 for whom efavirenz is
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co-infected with hepatitis C.
Triple NRTI regimens have potential advantages over
standard NNRTI-based ﬁrst-line regimens in Africa, as they
avoid drug interactions with TB therapy, can be taken by
women who may become pregnant and those with higher
CD4 counts, consist of fewer pills and spare two classes for
second-line after immunological/clinical failure where drug
resistance is likely. Whilst it is generally recognized that
triple NRTI regimens have poorer virological efﬁcacy than
NNRTI or protease inhibitor (PI)-based therapy (Gulick
et al. 2004; Bartlett et al. 2006) a ‘simpliﬁcation strategy’
for managing NNRTI toxicity and drug–drug interactions
by substituting with a third NRTI, either abacavir or
tenofovir, is also evolving (Gilks et al. 2006). Abacavir is
also an important potential backbone NRTI combined with
NNRTIs (WHO 2006). However, 3–8% of patients receiv-
ing abacavir in clinical studies in industrialized countries
develop a suspected HSR (Brothers et al. 2005), character-
ized by fever, rash, gastrointestinal and/or respiratory
symptoms, and lethargy or malaise, which usually appear
within 6 weeks. Symptoms worsen with continued therapy
but usually resolve on discontinuation. Restarting abacavir
results in a prompt return of symptoms, which may be more
severe and include life-threatening hypotension and death.
Standard practice in industrialized countries is to stop
abacavir for symptoms consistent with hypersensitivity and
neverrestartthedrug.AlthoughgeneticvariationsinHLA-B
have been associated with abacavir HSRs in some popula-
tions (Hughes et al. 2004), such tests are unlikely to be
available throughout Africa to guide its use. Thus whilst
rates of abacavirHSR arelikelyto be lowerin Africa than in
industrialized countries as a result of race and lower pre-
ART CD4 (Brothers et al. 2006), high rates of possible
reactions that cannot be conﬁrmed or may be confused with
malariaorotherinfectionsorimmunereconstitutiondisease
could render abacavir challenging to use in Africa, or
substantially reduce its use.
Nevirapine OR Abacavir (NORA) was therefore
designed to evaluate the safety of abacavir compared with
nevirapine in previously untreated African individuals with
advanced HIV disease initiating ARVs in a setting where all
patients were under close clinical supervision within the
DART trial.
Methods
Trial design
Nevirapine OR Abacavir was a 24-week randomized dou-
ble-blind trial conducted in two centres in Uganda (the Joint
Clinical Research Centre, Kampala and the MRC/UVRI
Uganda Research Unit on AIDS, Entebbe, Uganda), as a
nested substudy within DART (Reid et al. 2004). NORA
participantswererandomlyallocatedina1:1ratiotoreceive
zidovudineandlamivudine(co-formulatedascombivir)plus
either 300 mg abacavir and nevirapine placebo or abacavir
placebo and 200 mg nevirapine twice daily prescribed for
24 weeks (double dummy design). The dose of blinded
nevirapine or placebo was doubled from 200 mg once daily
to twice daily at 14 days. Participants experiencing adverse
events considered suspected reactions to abacavir or nevi-
rapine after discussion with the Project Leader in each site
weretobeunblinded(aftercompletionofcaserecordforms)
toavoidthepossibilityofrestartingabacavirornevirapinein
a participant experiencing a drug-related reaction. Other
participants needing to switch from blinded nevirapine/
abacavir (e.g. tostart anti-tuberculosis medications) were to
substitutetenofovirDFwithoutunblinding.After24 weeks,
participants continued combivir, substituting open-label
nevirapine or abacavir for active trial drug and continued
follow-up in DART.
Participants and sites
Symptomatic HIV-antibody positive adults aged 18 years
or older with CD4 <200 cells/mm
3 who had not previ-
ously received ARVs other than to prevent mother-
to-child HIV transmission and without concurrent acute
infections who were being enrolled into the DART trial
in Uganda were eligible for NORA unless they had
laboratory abnormalities contraindicating nevirapine or
were taking tuberculosis treatment (intensive or mainte-
nance phase). Every participant gave informed consent for
both NORA and DART, which received ethics approval
in Uganda and the UK. Staff in both sites received
standard training in abacavir hypersensitivity recogni-
tion and management prior to the trial using a standard
case deﬁnition (Brothers et al. 2005). In addition, all
NORA participants in NORA were issued with an
‘Abacavir Warning Card’.
Randomization
Randomization was undertaken by telephoning the local
Trials Centre attached to but separate from each of the
clinical sites, stratiﬁed by clinical centre, baseline CD4
count (0–99 or 100–199 cells/mm
3) and allocation to
clinical monitoring only (CMO) or laboratory plus clinical
monitoring (LCM) in the main DART trial. Blinded trial
drug was labelled with sequential study numbers according
to a pre-prepared randomization list generated by the Trial
Statistician using simple randomization within strata.
Randomization codes linking active nevirapine/abacavir
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drug) were only held by one statistician at each local Trial
Centre (who could therefore perform emergency unblin-
ding) and two statisticians at the coordinating centre in
London. Thus neither the patient, the treating physician,
data entry staff nor staff at the local Trials Centre knew
which arm the participant was allocated to.
Management and follow-up
Trial entry was the date of randomization. All DART
participants attend the study clinic 4 weekly, when a
nurse administers a standard symptom checklist and
adherence questionnaire, and dispenses a repeat ARV
prescription (28 days); participants are also asked to
return if they feel unwell. All participants see a doctor
and have a full blood count, liver and renal function
tests, and lymphocyte subsets measured at weeks 4 and
12, and then every 12 weeks. However, the laboratory
results are only returned to clinicians caring for CMO
participants in case of grade 4 toxicity or if clinically
indicated and lymphocyte subsets are not returned.
Laboratory tests may be requested for clinical indications
at any time. Serious adverse events (SAEs) according to
the International Conference on Harmonization Good
Clinical Practice (ICH-GCP) and new/recurrent WHO
stage 3 and 4 events (WHO 1990) are reported at
diagnosis: all other events are reported at routine follow-
up visits. All WHO stage 4 events are reviewed against
criteria for presumptive/deﬁnitive diagnosis by an End-
point Review Committee (blinded to allocated treatment),
who also review cause of death. All reported SAEs in
NORA were also reviewed blinded to allocated treat-
ment. Adherence was assessed by pill counts at 4-weekly
nurse visits, adjusting for late return to clinic (in 1–3%),
early attendance or dose escalation, but not adjusting for
periods off ARVs or for additional pills prescribed if a
patient knew they could not attend their next visit in
exactly 28 days.
Outcomes
The primary endpoint was any SAE which was deﬁnitely/
probably related or uncertain whether related to blinded
nevirapine/abacavir (serious adverse reaction – SAR)
occurring while on ARVs or within 30 days of stopping
ARVs. The original sample size of 600 provided 80%
power to detect a difference in rate of SARs between 15%
in one and 8% in the other arm using a two-sided chi-
squared test with a = 0.05. Following ICH guidelines,
SAEs were deﬁned as events not related to HIV only and
fatal, life-threatening, causing unplanned or prolonging
hospitalization, causing permanent or signiﬁcant disability,
or other important medical conditions. All suspected HSRs
(which carry a risk of life-threatening symptoms without
drug discontinuation) were considered ‘other important
medical conditions’. Secondary endpoints were adverse
events of any grade leading to permanent stopping of
blinded nevirapine/abacavir, and grade 4 events irrespec-
tive of whether or not they resulted in stopping nevirapine/
abacavir [toxicity graded accorded to minor modiﬁcation
of the AIDS Clinical Trials Group (ACTG) criteria (Divi-
sion of AIDS 1992)]. There was no requirement to report
laboratory or clinical grade 4 AEs as SAEs unless they met
the ICH-GCP criteria.
Statistical analysis
Time-to-event methods including Kaplan–Meier plots,
logrank test and Cox proportional hazards models were
used to compare randomized groups for time-to-event
outcomes. Categorical variables were compared between
randomized arms using exact tests, and continuous
variables using t-tests and rank-sum tests. All compari-
sons were as randomized (intent to treat): safety
analyses were restricted to time on blinded nevirapine/
abacavir plus 30 days (similar results including all
follow-up). Baseline values were those recorded nearest
to but before and within 6 weeks of randomization.
Generalized estimating equations (GEE, independent
correlation structure) were used to compare continuous
variables across randomized groups over time, using the
closest measurement to the scheduled assessment week
within equally spaced windows. All P-values are two
sided. All analyses were repeated with and without
stratiﬁcation for baseline CD4 cell count, centre and
randomization to CMO vs. LCM to conﬁrm no major
imbalances affecting results.
Results
Between 5 January 2004 and 28 October 2004, 600
individuals were randomized (Figure 1). A year after
enrolment, one participant (N) disclosed that they had
previously taken 3 months of Triomune (co-formulated
lamivudine/stavudine/nevirapine). As the number of other
participants with concealed prior exposure is unknown,
this participant was not excluded. Two further participants
(2N) had tuberculosis at screening: one concealed a recent
diagnosis from fear of not receiving ART, and one was
diagnosed after randomization from a screening sputum
sample; a further three participants (3A) had minor
eligibility violations (two neutrophils <0.5 · 10
9/l, 1 ALT/
AST >5 · ULN). Primary and secondary endpoint com-
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Figure 1 Participant disposition.
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population (297A, 297N). All but one participant started
allocated trial drugs within 3 days of randomization; this
last participant started on day 8.
Baseline characteristics
Baseline characteristics were broadly similar between the
two groups (Table 1). Fourteen of the 15 women who
reported previous ARVs to prevent mother-to-child HIV
transmission had taken single-dose nevirapine: the
remaining woman did not know which drug(s) she had
received. One hundred and twenty-ﬁve (42%) abacavir and
120 (40%) nevirapine participants were taking cotrimox-
azole prophylaxis or started it at randomization (median
CD4 104 cells/mm
3): only 11 (2%) and one (0.2%)
participants were taking ﬂuconazole or isoniazid prophy-
laxis, respectively.
Table 1 Baseline characteristics
Abacavir Nevirapine
Total participants 300 (100%) 300 (100%)
Randomization in main DART trial
Laboratory and clinical monitoring 150 (50%) 149 (50%)
Clinical monitoring only 150 (50%) 151 (50%)
Centre
Entebbe, Uganda 149 (50%) 151 (50%)
JCRC, Uganda 151 (50%) 149 (50%)
Sex
Male 83 (28%) 87 (29%)
Female 217 (72%) 213 (71%)
Age (years)
£30 43 (14%) 68 (23%)
>30–35 69 (23%) 55 (18%)
>35–40 75 (25%) 90 (30%)
>40–45 64 (21%) 41 (14%)
>45–50 31 (10%) 32 (11%)
>50 18 (6%) 14 (5%)
Median (IQR) 37.6 (31.9–42.3) 36.3 (30.7–41.4)
WHO disease stage
2 83 (28%) 76 (25%)
3 173 (58%) 157 (52%)
4 44 (15%) 67 (22%)
CD4 (cells/mm
3)
0–49 76 (25%) 88 (29%)
50–99 75 (25%) 62 (21%)
100–149 75 (25%) 84 (28%)
150–199 74 (25%) 66 (22%)
Median (IQR) [range] 99 (49–149) [1–199] 100 (40–145) [1–199]
Body mass index (BMI): median (IQR) 20.9 (18.9–23.5) 21.3 (19.3–23.8)
Haemoglobin (g/dl): mean (SD) 11.5 (1.8) 11.6 (1.7)
Neutrophils (·10
9/l): mean (SD) 1.5 (0.7) 1.6 (0.9)
Glomerular ﬁltration rate
(ml/min/1.73 m
2)*: mean (SD)
85 (27) 85 (20)
ALT (IU): mean (SD) 27 (19) 27 (16)
AST (IU): mean (SD) 37 (25) 37 (20)
Women prescribed ARVs to prevent
MTCT before entering DART (% of women)
4 (2%) 11 (5%)
Cotrimoxazole prophylaxis 120 (40%) 125 (42%)
The median CD4 at baseline is 99 rather than 99.5 cells/mm
3 (as designed), because one participant was randomized in the wrong CD4
stratum in error.
ARV, antiretroviral; WHO, world health organisation.
*Calculated according to the Cockcroft–Gault formula and adjusted for body surface area.
Including prophylaxis prescribed on the day of randomization.
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Five hundred and seventy (95%) participants (289A,
281N) completed 24 weeks: 24 participants died before
24 weeks (9A, 15N), ﬁve were lost to follow-up (1A, 4N)
and one (A) formally withdrew consent (Figure 1). Partic-
ipants reaching week 24 were transferred to open-label
nevirapine or abacavir and continue to be followed-up in
DART.
Adherence
There was no difference between randomized groups in
the proportion with >95% adherence according to 4-
weekly pill counts to combivir (global P = 0.84), blinded
abacavir/abacavir placebo (P = 0.60) or blinded nevira-
pine/nevirapine placebo (P = 0.96). In both groups and for
all drugs, the proportion reporting >95% adherence
increased over time, from 85% of participants at week 4
to 92% at week 12 and 94% at week 24. However, the
percentage of participants reporting that they had never
missed a dose decreased from 73% at 4 weeks to 61%
and 49% at 12 and 24 weeks with no difference
between arms (global P = 0.58), although the percentage
reporting that they had missed a dose in the last week
remained stable at 4–6%, again with no difference
between arms (global P = 0.55).
Serious adverse reactions (SARs, primary endpoint)
A total of 37 SAEs occurred in 36 participants (14A, 22N;
a second SAE occurred in one participant on open-label
nevirapine following discontinuation of blinded abacavir
for HSR), all on blinded drug or within 30 days of stopping
blinded trial drugs. Twenty (6A, 14N) were considered to
be SARs at independent review (deﬁnitely/probably related
or uncertain whether related to blinded trial drugs,
Table 2) occurring in six (2.0%) and 14 (4.7%) partici-
pants receiving abacavir and nevirapine respectively
[HR = 0.42 (95% CI 0.16–1.09), logrank P = 0.06, Fig-
ure 2]. The 20 SARs were one life-threatening event (N),
two hospitalizations (2N), and 17 other important medical
conditions (6A, 11N); only 10 (2A, 8N) were grade 3/4.
Three (3N) and one (N) SAR were also considered
uncertain whether related to cotrimoxazole and isoniazid
respectively. The six abacavir SARs were in three men and
three women, whereas the 14 nevirapine SARs were in
three men and 11 women (P = 0.19 for heterogeneity with
sex). Seven additional SAEs (3A, 4N) were originally
reported as uncertain whether related to blinded trial drugs
by the clinical investigator, but were judged unlikely to be
related at independent review (Table 2).
In 19 of 20 participants, the SAR was consistent with a
suspected HSR: six abacavir (2.0%, 95% CI 0.7–4.3%) vs.
13 nevirapine (4.3%, 95% CI 2.3–7.3%). Broadly similar
proportions of those with suspected HSR on abacavir and
nevirapine had fever (4/6A, 9/13N); respiratory (4A, 7N),
constitutional (3A, 7N), or gastrointestinal (2A, 5N)
symptoms; rash (6A, 10N) and oral/mucosal involvement
(3A, 6N): but hepatic involvement was only seen in the
nevirapine group (4N) (Table 3). All participants with
respiratory symptoms in the nevirapine group had either
rash (n = 4) or hepatic involvement plus constitutional
symptoms and fever (n = 3). Fifteen of the 16 rashes were
disseminated; three were grade 4 (3N), one grade 3 (A) and
11 (5A, 6N) grade 1/2. No participant had Stevens–
Johnson syndrome. The remaining SAR was asymptomatic
grade 4 hepatitis (N). In total, ﬁve of the 14 nevirapine
participants with SARs had grade 4 LFT elevations
(including the one with asymptomatic hepatitis alone) and
two had grade 3 LFTs, compared with none of the six
abacavir participants.
The 17 (9A, 8N) SAEs considered unlikely to be related
to blinded drug were anaemia (n = 7, one fatal), pancyto-
penia/haematemesis (one fatal), sepsis/haematemesis (one
fatal), death from sudden/unexpected cause/death at home
[two at weeks 4 (N) and 9 (A), neither with any recorded
interruption in blinded drugs], indeterminate cerebral
disease (fatal), head injury, DVT, duodenal ulcer/hae-
matemesis, fever (uncertain whether related to rabies
vaccination), and rash (related to open label nevirapine
following discontinuation of blinded abacavir for a previ-
ous SAR) (Table 2).
Grade 4 adverse events
There were signiﬁcantly more grade 4 AE in the nevirapine
than in the abacavir arm [98 (33%) vs. 65 (22%)
participants, rates 93 and 61 per 100 person years,
P = 0.003]. The majority were neutropenia (47A, 73N) or
anaemia (19A, 15N). Only nine participants (9N) ever had
grade 4 (>10 · upper limit of normal) elevations in LFTs
(including one with asymptomatic hepatitis and four with
suspected HSR reported as SARs). Four resolved after
substitution of tenofovir for nevirapine (all four reported as
SARs), and ﬁve resolved without substituting for nevira-
pine (4 had one grade 4 measurement only, the remaining
one (reported as a SAR) was maintained on open-label
nevirapine). Of the 196 grade 4 AE, only 31 (13A, 18N)
were considered by the clinical investigator to be deﬁnitely/
probably or uncertain whether related to blinded trial
drugs [in 13 (4%) vs. 18 (6%) participants, respectively],
with no evidence of a difference between randomized
groups (rates 9.9 and 14.5 per 100 person-years, P = 0.30).
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Blinded trial drug was prescribed for 96.8% and 92.3% of
person-time to 24 weeks in the abacavir and nevirapine
arms, respectively. In total 14 (4.7%) and 30 (10.0%)
participants discontinued blinded trial drug, respectively
(exact P = 0.02, P = 0.04 in strictly eligible population).
Twenty-one discontinuations were for toxicity [6A (2.0%)
Table 2 Grade 4 and serious AEs and ARs
Abacavir Nevirapine
Events Reactions* Events Reactions*
Total SAE/SAR 15 6 [3] 22 14 [4]
Grade 4 7 [2] 11 5 [2]
Suspected HSR 44
Acute asymptomatic hepatitis (LFTs) 1 1
Anaemia 4 3 [1]
Pancytopenia + haematemesis 1 [1]
Sepsis + haematemesis 1 [1]
Deep vein thrombosis 1 [1]
Head injury 1
Indeterminate cerebral disease 1
Urticarial rash + fever + mucosal symptoms 1§
Grade 1–3 7 6 10 9 [1]
Suspected HSR 6 6 9 9
Duodenal ulcer + haematemesis 1
Fever + constitutional symptoms 1– [1–]
Death from unknown cause 1 [1] 1 [1]
Participants with at least one SAE/SAR (% of randomized) 14 (5%) 6 (2%) 22 (7%) 14 (5%)
Rate (events per 100 person years) 11.4 4.6 17.7 11.2
Grade 4 AE/AR not reported as SAE/SAR (not reviewed) 73 [11] 105 [11]
Anaemia (<6.5 g/dl) 14 13
Neutropenia (<0.5 · 10
9/l) 47 [9] 73 [11]
Leucopenia (<1.0 · 10
9/l) 5 5
Thrombocytopenia (<20 · 10
9/l) 1 1
Raised bilirubin (>5.0 · ULN) 2 3
Raised creatinine (>6.0 · ULN) 1
Raised liver enzymes (>10.0 · ULN) 7
Hyponatraemia (<116 mmol/l) 1 1
Myopathy 1 (1)
Paralytic ileus 1
Convulsions 2 (1)
Participants with at least one grade 4 AE/AR
not reported as SAE/SAR (% of randomized**)
61 (20%) 11 (4%) 92 (31%) 11 (4%)
Total grade 4 AE/AR (including grade 4 SAE/SAR) 80 13 116 18
Rate (events per 100 PY) 60.7 9.9 93.2 14.5
Participants with at least one grade 4 AE/AR (% of randomized) 65 (22%) 13 (4%) 98 (32%) 18 (6%)
Grade 4 AE are new grade 4 AE reported during the ﬁrst 24 weeks which were not pre-existing at randomization and excluding recurrences
of the same event. Grade 4 laboratory results are returned to clinicians (in both LCM and CMO arms, see Methods), but there was no
requirement to report a clinical or laboratory grade 4 AE as an SAE unless the event met the ICH-GCP criteria for SAE.
SAE, serious adverse event; SAR, serious adverse reaction; HSR, hypersensitivity reaction.
*Deﬁnitely/probably related or uncertain whether related to blinded trial drugs.
For SAE: number of conﬁrmed SARs at independent SAE review [additional SAE originally reported by the clinical investigator as
uncertain whether related to blinded trial drugs, but judged unlikely to be related or unrelated to blinded trial drugs at independent review].
For grade 4 AE (not reviewed): [any grade 4 event reported by the clinical investigator as deﬁnitely/probably related or uncertain whether
related to blinded trial drugs].
600 randomized, 300 to abacavir and 300 to nevirapine.
§Related to open label nevirapine following discontinuation of blinded abacavir for a previous HSR.
–Considered uncertain whether related to rabies vaccination on independent review but unlikely to be related to blinded trial drug.
**Participants with SAE reported could have laboratory Grade 4 AE at the same time which did not meet ICH-GCP SAE criteria.
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participants with SARs: the toxicity was rash/suspected
HSR (6A, 13N) and/or hepatotoxicity (4N) in all cases.
The remaining 19 patients were to start tuberculosis
therapy [6A (2.0%) vs. 13N (4.3%), respectively], or for
other reasons [pregnancy (1N), personal (2A, 1N)]. How-
ever, two of the 13 discontinuing blinded trial drug to start
tuberculosis therapy in the nevirapine arm had tuberculosis
which could have been identiﬁed at screening. Time to AE
causing discontinuation did not differ signiﬁcantly between
the two groups [median 32 days (IQR 25–59, range 8–85)
in the nevirapine vs. 44 days (12–66, 4–112) in the
abacavir group; ranksum P = 0.70].
Unblinding
Twenty-two participants (6A, 16N) were unblinded before
24 weeks – all but one (N, pregnancy) because of toxicity
leading to discontinuation of blinded trial drugs described
above. Sixteen (4A, 12N) of the 22 substituted tenofovir
according to protocol and six (2A, 4N) substituted open-
label nevirapine. Of the four participants who therefore
remained on active nevirapine, one unblinded for preg-
nancy, one for fever/constitutional symptoms subsequently
judged not related to blinded trial drugs and uncertain
whether related to rabies vaccine (Table 2), and two for
suspected HSRs (grade 1 and 2 reactions, respectively).
Other substitutions and discontinuations whilst retaining
blinding
A further 20 (7A, 13N) participants substituted open-label
tenofovir for blinded trial drugs without unblinding (most
following tuberculosis diagnosis). Only two participants
(1A, 1N) stopped all antiretrovirals for >31 days (both for
personal reasons). Forty-ﬁve participants (22A, 23N)
substituted stavudine for zidovudine, because of anaemia
(16A, 17N) and/or neutropenia (5A, 8N), or myopathy
(1A). No other substitutions occurred during the 24-week
study, and no participant switched to second-line therapy.
Changes in laboratory parameters of toxicity
The nevirapine arm had signiﬁcantly greater increases from
baseline in absolute levels of liver function tests (ALT
global P = 0.003, AST P = 0.07) compared with the
abacavir arm, and signiﬁcantly higher grades of liver
function test toxicity (ALT P = 0.006, AST P = 0.05). In
contrast, the nevirapine arm had small but signiﬁcantly
greater increases from baseline in glomerular ﬁltration rate
calculated by Cockcroft–Gault (GFR) compared with the
abacavir arm (global P = 0.01, e.g. mean +1 vs. +9 in the
nevirapine arm at week 12, t-test P = 0.007), and lower
grades of GFR toxicity (P = 0.03). Early haemoglobin
decreases were smaller in the abacavir arm (mean )0.3 g/dl
vs. )0.6 g/dl in the nevirapine arm at week 4, t-test
P = 0.02) although comparable by week 24 (global
P = 0.09) and there was no overall difference in toxicity
(P = 0.90). Similarly, there was a non-signiﬁcant trend
towards smaller decreases in neutrophils in the abacavir
arm (P = 0.43), and signiﬁcantly lower grades of toxicity
(P = 0.03). There was no difference between nevirapine
and abacavir arms in other laboratory parameters of
toxicity.
Discussion
This is the ﬁrst blinded study to compare reactions to
abacavir and nevirapine. The low rate recorded for
abacavir (2.0%, 95% CI 0.7–4.3%) demonstrates that the
potential for HSRs should not preclude the use of this drug
in Africa and other resource-limited settings rolling out
ART. In particular, in spite of the higher background rates
of intercurrent infection and malaria, the only abacavir
discontinuations for toxicity were for HSRs conﬁrmed as
serious adverse reactions at independent review. Clinicians
in DART did not have any previous experience of using
abacavir, showing that with focussed HSR training, clinical
teams in resource-limited settings can identify and manage
abacavir reactions appropriately. In addition, none of the
six abacavir reactions were grade 4, suggesting that
patients in these settings can present promptly to clinical
services with suspected HSR symptoms if this is explained
well. By comparison, 4.7% (95% CI 2.6–7.7%) of the
nevirapine group developed serious adverse reactions, and
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nevirapine were grade 4.
Nevirapine OR Abacavir is the ﬁrst trial to compare all
adverse reactions between abacavir and nevirapine using
blinded drugs. Results indicate a higher level of discon-
tinuation of nevirapine than of abacavir overall and a trend
towards a higher rate of serious adverse reactions and
discontinuation for toxicity with nevirapine. Nevirapine is
widely used in resource-limited settings, but has the
potential for life-threatening reactions. These data suggest
that, based on toxicity proﬁle, abacavir could be used more
widely in resource-limited settings without major safety
concerns. We observed considerable overlap in the clinical
manifestations of nevirapine and abacavir related reac-
tions, noting however, that hepatotoxicity only occurred
with nevirapine. These data suggest that whilst the use of
abacavir and nevirapine in combination is attractive
(particularly with lamivudine as part of the ﬁxed dose
combination, Kivexa), strategies for managing reactions
need to be considered carefully and will probably include
liver function test results. However, we have not yet
assessed the incidence of viral hepatitis in DART, and
therefore its potential contribution to the hepatotoxicity
observed is unknown. As expected, there were more
LFT abnormalities in the nevirapine group: the clinical
signiﬁcance of the small differences in other laboratory
parameters is unclear.
Limitations of our study include the fact that the
toxicity rates in NORA were lower than originally
anticipated, and therefore the study was slightly under-
powered to determine the signiﬁcance of the 50%
reduction observed. The contribution of pharmacoge-
nomics to the lower than anticipated toxicity rate is
unknown. The NORA population is likely to differ
substantially from previously studied groups in major
MHC alleles such as HLA-B*5701 which may play a
role in HSR (Hughes et al. 2004; Martin et al. 2006); a
study of polymorhpisms in NORA is underway. Of note,
one participant with an abacavir reaction was incorrectly
switched to open label nevirapine after unblinding and
experienced a nevirapine reaction 4 weeks later, sug-
gesting that underlying susceptibility to HSR may be
important. Two participants with suspected HSRs on
blinded nevirapine subsequently continued open-label
drug. It is therefore possible that more nevirapine
reactions could have been treated through were the
participants not part of a blinded study, although this
does not affect the estimates of the rates of such SARs.
Finally, DART does not include prospective HIV RNA
viral load data, so the virological efﬁcacy of abacavir vs.
nevirapine in this population is not known, although
triple NRTI regimens have had poorer virological
Table 3 Symptoms occurring in participants with suspected HSRs
Total Abacavir Nevirapine
Suspected HSRs 19 6 13
Predominant symptom
complex:
Rash, erythematous, multiforme 1 0 1
Rash, maculopapular and/or
erythematous
Rash alone 2 1 1
+ Constitutional symptoms only 3 1 2
+ Mucosal symptoms only 5 2 3
+ Mucosal + constitutional
symptoms
20 2
+ Mucosal symptoms + hepatitis 1 0 1
Rash, urticarial
+ Constitutional symptoms only 1 1 0
+ Mucosal + constitutional
symptoms
11 0
Acute hepatitis + constitutional
symptoms
30 3
Individual skin components*: 16 6 10
Pruritis 11 4 7
Urticaria 5 3 2
Erythema multiforme 2 1 1
Mucous membrane involvement 4 1 3
Macular/maculopapular rash 11 3 8
Vesicular 1 1 0
Erythema 6 3 3
Other symptom components*
Fever/chills 13 4 9
Malaise/fatigue 7 2 5
Myalgia/arthralgia 4 0 4
Headache 7 3 4
Conjunctivitis 3 3 0
Stomatitis 4 0 4
Other mucosal lesions 2 0 2
Nausea/vomiting 4 0 4
Diarrhoea 1 1 0
Abdominal pain 4 1 3
Cough/pharyngitis 11 4 7
Dyspnoea/wheezing 0 0 0
Oedema 5 1 4
Tachycardia 2 0 2
Hypotension 1 1 0
Other 2 1 1
LFT toxicity
Grade 4 4§ 0 4§
Grade 3 2 0 2
HSR, hypersensitivity reaction.
*Each component present (to any degree) or not present in the
reaction. Therefore each participant may report multiple symp-
toms, in contrast to ‘predominant symptom complex’ where each
participant appears only once.
Burning sensation to both feet.
Jaundice.
§One additional SAR (asymptomatic hepatitis) also had grade 4
LFT elevations.
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tests are now being performed retrospectively.
In summary, in African patients initiating ARVs with
low CD4 counts, there was a lower discontinuation rate
of abacavir and a trend to a lower rate of SARs compared
with nevirapine. With the exception of hepatotoxicity,
there was considerable overlap in the clinical reactions to
abacavir and nevirapine in this population. We estimate
the rate of abacavir-HSR to be 2% in Uganda. Assessment
of genetic polymorphisms that may, at least in part,
explain why the event rate is lower than observed in
industrialized countries is ongoing. These data suggest
that the potential for abacavir HSR should not prevent its
use in rollout as one of the recommended ﬁrst-line NRTI
options in the most recent WHO treatment guidelines
(WHO 2006).
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